Nalbuphine in ARDS Patients After Surgery
Acute Respiratory Distress Syndrome
About this trial
This is an interventional treatment trial for Acute Respiratory Distress Syndrome
Eligibility Criteria
Inclusion Criteria: Had undergone surgical treatment within 7 days before enrollment; Meet the diagnostic criteria for ARDS proposed at the 2011 Berlin ARDS Definition Conference; Age ≥18 years old, gender unlimited; Patients admitted to ICU with CPOT score ≥3; Stay in ICU ≥48h; Sign the informed consent form. Exclusion Criteria: APACHE II score ≥23 points; Patients with esophageal reflux disease and severe gastrointestinal injury have AGI score ≥3; Long-term use of narcotic analgesics, hypnotics and psychotropic drugs; Alcohol withdrawal symptoms; Severe liver dysfunction (Child-Pugh grade C); Patients with bronchial asthma and myasthenia gravis; Patients with severe craniocerebral injury, brain tumor, and increased intracranial pressure are prone to respiratory depression; Patients undergoing cardiac surgery under cardiopulmonary bypass; Patients who have been enrolled in other clinical trials; Study patients with drug allergy or other contraindications; Pregnant or lactating women; The patient himself or his legally authorized representative is unwilling to sign the informed consent;
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Nalbuphine group
Sufentanil group
40 mg of nalbuphine was diluted into 50 mL solution, the load dose was 0.1mg/kg, the maintenance dose was 0.04-0.08mg/kg/h, the CPOT score was <2, and the daily maximum dose was 160mg.
0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was <2 points.